treatment of human glioblastoma
Abstract # 3731, Session: Imaging in Preclinical and Clinical
Poster Session: Tuesday, April 15, 2008, 8:00 a.m. to
12:00 p.m. PT
- Identification of novel synergistic targets RACK-1 and galectin-1 for
rational drug combinations with PI3 Kinase inhibitors using siRNA
synthetic lethality screening
Abstract # 2761, Session: Signal Transduction and Therapeutics
Poster Session: Monday, April 14, 2008, 1:00 p.m. to
5:00 p.m. P.T.
- Phosphatidylinositol 3-kinase stimulates the proliferation of
bronchioalveolar stem cells in mouse models of oncogenic K-ras-
induced lung cancer
Abstract # 5408, Session: Stem Cells
Poster Session: Wednesday, April 16, 2008, 8:00 a.m. to
12:00 p.m. P.T.
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.
Forward Looking Statements
In order to provide Oncothyreon's investors with an understanding of
its current intentions and future prospects, this release contains
statements that are forward looking, including statements related to future
clinical development plans for PX-12 and PX-866. These forward-looking
statements represent Oncothyreon's intentions, plans, expectations and
beliefs and are based on its management's experience and assessment of
historical and future trends and the application of key assumptions
relating to future events an
|SOURCE Oncothyreon Inc.|
Copyright©2008 PR Newswire.
All rights reserved